Advertisement #1
Home Clinical development Phase III

Phase III

Phase III

Trastuzumab Deruxtecan Is an Effective Option for Difficult-to-treat HER2-expressing Solid Tumors

Editorial Team -

Mirvetuximab Soravtansine Improves Survival in Women With Recurrent Ovarian Cancer

Editorial Team -

Study Shows Nivolumab Reduces Risk of Disease Progression in Advanced, Untreated Hodgkin Lymphoma

Editorial Team -

Adjuvant Osimertinib Significantly Improves Survival in Patients With Resected EGFR-Mutated NSCLC

Editorial Team -

Radiation Can Be Safely Omitted in Select Patients With Locally Advanced Rectal Cancer

Editorial Team -

Vorasidenib Significantly Improves Progression-free Survival in Grade 2 Glioma with IDH Mutation

Editorial Team -

Combination of Olaparib + Durvalumab Prolonged Progression-Free Survival in Advanced Ovarian Cancer

Editorial Team -

Ribociclib Added to Hormonal Therapy Helps Reduce Risk of Recurrence of a Subtype of...

Editorial Team -

What to expect at ASCO ’23: Lilly’s Progress in Treatment of Breast Cancer and...

Editorial Team -

MIRASOL Trial: Elahere® Shows Survival Benefit in FRα-Positive Platinum-Resistant Ovarian Cancer

Editorial Team -
123...9Page 1 of 9

LATEST NEWS

Advertisment #12
© 2001 - 2023 Sunvalley Communication, LLC. All Rights Reserved.

X